Rapid Micro Biosystems, Inc. (RPID) Stock

Rapid Micro Biosystems, Inc. (RPID) is a Technology stock trading at $1.67 (as of 2026-08-20), with a market capitalization of $80.74M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in North America, Europe, and Asia. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and comprehensive customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides installation and verification, technical training, and support services. Its solutions are used in environmental monitoring, water testing, bioburden, and sterility release testing applications. The company was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. Rapid Micro Biosystems, Inc. was incorporated in 2006 and is headquartered in Lowell, Massachusetts.

Understand Rapid Micro Biosystems, Inc.: how it makes money

Rapid Micro Biosystems provides the Growth Direct platform for detecting microbial contamination in the manufacture of pharmaceutical, medical device, and personal care products, it makes money by selling Growth Direct systems, proprietary consumables, and related software and validation and support services.

Profit in the Growth Direct model is tied to how many customer systems are validated and in the field, because that base drives proprietary consumables pull-through and supports Recurring Revenue over time.

Revenue by segment (latest quarter)
Systems$0.0B
Services$0.0B

Business quality (Weak): The company is building a validated installed base tied to recurring consumables, but the latest quarter shows very small reported revenue and a deeply negative operating margin, so near-term profitability remains a key risk.

Bull case

  • Platform designed to create repeat use: Growth Direct includes Growth Direct system and proprietary consumables, and investors track Recurring Revenue.
  • Measured progress in customer validation footprint: Cumulative Systems Validated is 137, and Validated Systems in the Field is 68 (counts).
  • Validation milestones suggest target-market penetration: Approved CAR-T Manufacturers is 100% (percent).

Bear case

  • Scale and profitability are still weak: For the quarter ended 2026-03-31, revenue is reported as 0.0B, gross margin is 4.6%, and operating margin is -173.1%.
  • Limited validation momentum in the latest quarter: Customer Systems Validated (Completed in Quarter) is 3.0 (count).
  • Non-systems monetization appears limited in the reported data: Service Revenue is 0.0B (USD_B) in the provided candidates.
Valuation — source: SEC EDGAR (first-party)
Price$1.67
Market Cap$80.74M
Price / Book4.55
Price / Sales2.53
FCF Yield-108.3%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$33.59M
Net Margin-140.3%
Revenue Growth (YoY)19.7%
EPS Growth (YoY)-2.8%
FCF Growth (YoY)-29.9%
Financial Health — source: SEC EDGAR
Altman Z-Score-9.65 (distress)
Valuation vs Sector & Industry
Sector P/E (Technology)33.9
Industry P/E (Measuring & Control Equipment)51.8
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBain Capital Life Sciences Investors, LLC ($19.15M)
Institutional Holders Tracked10
Company
SectorTechnology
IndustryMeasuring & Control Equipment
CEORobert G. Spignesi Jr.
Employees163
CountryUS
IPO Date2021-07-15

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Pacific Biosciences of California, Inc. (PACB)
  • Harvard Bioscience, Inc. (HBIO)
  • Quanterix Corporation (QTRX)
  • Nautilus Biotechnology, Inc. (NAUT)
  • Seer, Inc. (SEER)
  • Precipio, Inc. (PRPO)
  • Bionano Genomics, Inc. (BNGO)
  • Astrotech Corporation (ASTC)
RPID earnings history · RPID institutional & insider holders · RPID KPIs & operating metrics · RPID financials · RPID investor presentations & press releases · RPID SEC filings · RPID peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.